By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



3489 Canterbury Place

South Surrey  British Columbia  V3S 0G8  Canada
Phone: 604-542-5059 Fax: 604-542-5069



Company News
biOasis Announces Voting Results For 2017 Annual Meeting 9/22/2017 6:30:25 AM
biOasis Announces Rob Hutchison, Founder, To Retire As Chairman & Board Member 9/19/2017 7:14:53 AM
biOasis Announces Formation Of Scientific Advisory Board To Advance The Science For The Company’s Blood-Brain Barrier Drug Delivery Platform 9/7/2017 11:09:32 AM
biOasis Enters Into A License Agreement With Vaccinex, Inc. 9/23/2016 1:34:14 PM
biOasis To Present At The 1st Annual Neuroscience BioPartnering And Investment Forum In New York On February 23, 2016 2/12/2016 10:17:27 AM
biOasis' BT2111-Herceptin(R) Program Achieves Significant Positive Results From Antibody Dependent Cell-Mediated Cytotoxicity Assay 3/13/2012 7:25:38 AM
biOasis Announces Transcend Vector Results With a Therapeutic Antibody That Targets Metastatic Breast Cancer 7/6/2011 10:16:51 AM
biOasis Director Resigns 6/24/2011 10:49:10 AM
biOasis to Present on Drug Delivery at International Conference on Cerebral Vascular Biology 6/22/2011 9:18:51 AM
biOasis Initiates Transcend Vector Program Targeting Treatments for CNS Symptoms of Lysosomal Storage Disorders 5/11/2011 9:47:35 AM